Harnessing the Full Potential of Therapeutics With Site-Directed Precise Medicines
Our discovery that oxMIF is generated exclusively in the oxidative environment at sites of inflammation provides the basis for a groundbreaking and versatile approach to direct therapeutics exclusively to diseased sites.
Candidate
Entity & Indication
Target
| Discovery
| Pre-clinical
| Phase 1
Immunology
Oncology
ON104
ON-08
ON203
ON102
Therapeutic mAb
Rheumatoid Arthritis & Nephritis
Therapeutic bispecific mAb
Alzheimer‘s & MS
Therapeutic mAb
Colorectal, Lung Cancer
Radioimmunoconjugate diagnostic
Cancer & Inflammation
oxMIF
oxMIF
oxMIF
oxMIF
Immunology: ON104
Therapeutic mAb - Rheumatoid Arthritis and Nephritis
Immunology: ON-08
Therapeutic bispecific mAb - Alzheimer‘s & MS
Oncology: ON203
Therapeutic mAb - Colorectal, Lung Cancer
Oncology: ON102
Radioimmunoconjugate diagnostic - Cancer & Inflammation
Current candidates:
ON104 is a second-generation monoclonal anti-oxMIF antibody with abolished effector functions, tailored to the therapeutic needs of patients living with chronic inflammatory and autoimmune disorders. ON104 neutralizes the pleiotropic disease promoting activities of oxMIF. In particular, as oxMIF can override the immunosuppressive effects of glucocorticoids, ON104 synergizes with current immunosuppressant therapeutics.
Currently, OncoOne is advancing ON104 through late-stage pre-clinical development for indications like Rheumatoid Arthritis (RA), and Nephritis. Optimized bio-physiochemical properties of ON104 support a high-dose formulation so that patients can perform self-injections at home using an autoinjector pen.
ON203 is a second-generation monoclonal anti-oxMIF antibody designed to address the specific therapeutic requirements of patients with solid tumors. This antibody has been optimized for enhanced tumor penetration and improved pharmacokinetic properties. ON203 effectively inhibits oxMIF-mediated pro-tumorigenic functions and demonstrates cytotoxic functions by inducing antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), offering significant therapeutic potential in solid tumors. Its mechanism of action allows for its use either as a standalone treatment or in combination with standard-of-care therapies.
ON203 is ready for filing IND/IMPD and to address the unmet medical needs of patients facing solid tumors of the colon and the lung in the clinic.
Current candidates:
ON104 is a second-generation monoclonal anti-oxMIF antibody with abolished effector functions, tailored to the therapeutic needs of patients living with chronic inflammatory and autoimmune disorders. ON104 neutralizes the pleiotropic disease promoting activities of oxMIF. In particular, as oxMIF can override the immunosuppressive effects of glucocorticoids, ON104 synergizes with current immunosuppressant therapeutics.
Currently, OncoOne is advancing ON104 through late-stage pre-clinical development for indications like Rheumatoid Arthritis (RA) and Nephritis. Optimized bio-physiochemical properties of ON104 support a high-dose formulation so that patients can perform self-injections at home using an autoinjector pen.
ON203 is a second-generation monoclonal anti-oxMIF antibody designed to address the specific therapeutic requirements of patients with solid tumors. This antibody has been optimized for enhanced tumor penetration and improved pharmacokinetic properties. ON203 effectively inhibits oxMIF-mediated pro-tumorigenic functions and demonstrates cytotoxic functions by inducing antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), offering significant therapeutic potential in solid tumors. Its mechanism of action allows for its use either as a standalone treatment or in combination with standard-of-care therapies.
ON203 is ready for filing IND/IMPD and to address the unmet medical needs of patients facing solid tumors of the colon and the lung in the clinic.
oxMIF: We Discovered It, We Named It, We Are Drugging It
